| Needs review |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 1/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 2/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 2/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 3 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 3/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 3/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 4 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 4/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 4/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 5 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 5/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 5/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 6 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 6/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 6/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 7 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 7/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 7/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 8 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 8/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 8/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 9 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 9/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 9/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 10 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 10/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 10/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 11 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 11/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 11/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 12 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 12/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 12/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 13 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 13/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 13/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 14 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 14/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 14/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 15 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 15/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 16 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 16/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 17 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 17/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 17/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 18 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 18/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 19 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 19/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 19/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 20 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 20/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 21 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 21/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 22 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 22/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 23 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 23/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 24 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 24/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 24/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 25 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 25/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 26 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 26/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 27 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 27/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 28 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 28/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 29 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 29/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 30 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 30/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 31 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 31/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 31/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 32 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 32/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 33 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 33/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 34 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 34/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 35 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 35/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 36 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 36/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 37 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 37/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 37/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 38 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 38/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 39 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 39/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 40 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 40/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 40/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 41 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 41/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 42 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 42/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 43 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 43/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 44 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 44/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 44/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 45 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 45/Signature 1 |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models/Experiment 1 |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models/Experiment 1/Signature 1 |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models/Experiment 1/Signature 2 |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models/Experiment 2 |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models/Experiment 2/Signature 1 |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models/Experiment 2/Signature 2 |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models/Experiment 3 |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models/Experiment 3/Signature 1 |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models/Experiment 3/Signature 2 |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models/Experiment 4 |
| A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models/Experiment 4/Signature 1 |
| A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease |
| A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease/Experiment 1 |
| A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease/Experiment 1/Signature 1 |
| A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease/Experiment 1/Signature 2 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 1/Signature 1 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 1/Signature 2 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 2 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 3 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 3/Signature 1 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 3/Signature 2 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 5 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 5/Signature 1 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 5/Signature 2 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 6 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 6/Signature 1 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 6/Signature 2 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 7 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 7/Signature 1 |
| Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 7/Signature 2 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 1/Signature 1 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2/Signature 1 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2/Signature 2 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 3 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 3/Signature 1 |
| Alterations in gut microbiota and host transcriptome of patients with coronary artery disease |
| Alterations in gut microbiota and host transcriptome of patients with coronary artery disease/Experiment 1 |
| Alterations in gut microbiota and host transcriptome of patients with coronary artery disease/Experiment 1/Signature 1 |
| Alterations in gut microbiota and host transcriptome of patients with coronary artery disease/Experiment 1/Signature 2 |
| Alterations in the Gut Microbiome of Young Children with Airway Allergic Disease Revealed by Next-Generation Sequencing |
| Alterations in the Gut Microbiome of Young Children with Airway Allergic Disease Revealed by Next-Generation Sequencing/Experiment 1 |
| Alterations in the Gut Microbiome of Young Children with Airway Allergic Disease Revealed by Next-Generation Sequencing/Experiment 1/Signature 1 |
| Alterations in the Gut Microbiome of Young Children with Airway Allergic Disease Revealed by Next-Generation Sequencing/Experiment 2 |
| Alterations in the Gut Microbiome of Young Children with Airway Allergic Disease Revealed by Next-Generation Sequencing/Experiment 2/Signature 1 |
| Alterations in the Gut Microbiome of Young Children with Airway Allergic Disease Revealed by Next-Generation Sequencing/Experiment 3 |
| Alterations in the intestinal microbiome and mental health status of workers in an underground tunnel environment |
| Alterations in the intestinal microbiome and mental health status of workers in an underground tunnel environment/Experiment 1 |
| Alterations in the intestinal microbiome and mental health status of workers in an underground tunnel environment/Experiment 1/Signature 1 |
| Alterations in the intestinal microbiome and mental health status of workers in an underground tunnel environment/Experiment 1/Signature 2 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2/Signature 1 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2/Signature 2 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 4 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 4/Signature 1 |
| Alterations of the vaginal microbiome in healthy pregnant women positive for group B Streptococcus colonization during the third trimester |
| Alterations of the vaginal microbiome in healthy pregnant women positive for group B Streptococcus colonization during the third trimester/Experiment 1 |
| Alterations of the vaginal microbiome in healthy pregnant women positive for group B Streptococcus colonization during the third trimester/Experiment 1/Signature 1 |
| Alterations of the vaginal microbiome in healthy pregnant women positive for group B Streptococcus colonization during the third trimester/Experiment 1/Signature 2 |
| Amelioration of Colitis by a Gut Bacterial Consortium Producing Anti-Inflammatory Secondary Bile Acids |
| Amelioration of Colitis by a Gut Bacterial Consortium Producing Anti-Inflammatory Secondary Bile Acids/Experiment 1 |
| Amelioration of Colitis by a Gut Bacterial Consortium Producing Anti-Inflammatory Secondary Bile Acids/Experiment 1/Signature 1 |
| Amelioration of Colitis by a Gut Bacterial Consortium Producing Anti-Inflammatory Secondary Bile Acids/Experiment 1/Signature 2 |
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2 |
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2/Signature 1 |
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2/Signature 2 |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets/Experiment 1 |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets/Experiment 1/Signature 1 |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets/Experiment 1/Signature 2 |
| Analysis of the Conjunctival Microbiome in Patients with Atopic Keratoconjunctivitis and Healthy Individuals/Experiment 1/Signature 3 |
| Analysis on the change of gut microbiota and metabolome in lung transplant patients/Experiment 1 |
| Analysis on the change of gut microbiota and metabolome in lung transplant patients/Experiment 1/Signature 1 |
| Analysis on the change of gut microbiota and metabolome in lung transplant patients/Experiment 1/Signature 2 |
| Analysis on the change of gut microbiota and metabolome in lung transplant patients/Experiment 2 |
| Analysis on the change of gut microbiota and metabolome in lung transplant patients/Experiment 2/Signature 1 |
| Analysis on the change of gut microbiota and metabolome in lung transplant patients/Experiment 2/Signature 2 |
| Analysis on the change of gut microbiota and metabolome in lung transplant patients/Experiment 3 |
| Analysis on the change of gut microbiota and metabolome in lung transplant patients/Experiment 3/Signature 1 |
| Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites |
| Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites/Experiment 1 |
| Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites/Experiment 1/Signature 1 |
| Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites/Experiment 1/Signature 2 |
| Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites/Experiment 2 |
| Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites/Experiment 3 |
| Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites/Experiment 4 |
| Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites/Experiment 4/Signature 1 |
| Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome/Experiment 3/Signature 1 |
| Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome/Experiment 4/Signature 2 |
| Association between Parkinson's disease and the faecal eukaryotic microbiota |
| Association between Parkinson's disease and the faecal eukaryotic microbiota/Experiment 1 |
| Association between Parkinson's disease and the faecal eukaryotic microbiota/Experiment 1/Signature 1 |
| Association between Parkinson's disease and the faecal eukaryotic microbiota/Experiment 1/Signature 2 |
| Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV |
| Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV/Experiment 1 |
| Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV/Experiment 1/Signature 1 |
| Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV/Experiment 1/Signature 2 |
| Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV/Experiment 2 |
| Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV/Experiment 2/Signature 1 |
| Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV/Experiment 2/Signature 2 |
| Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV/Experiment 3 |
| Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV/Experiment 3/Signature 1 |
| Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV/Experiment 3/Signature 2 |
| Association of the Cervical Microbiota With Pregnancy Outcome in a Subfertile Population Undergoing In Vitro Fertilization: A Case-Control Study |
| Association of the Cervical Microbiota With Pregnancy Outcome in a Subfertile Population Undergoing In Vitro Fertilization: A Case-Control Study/Experiment 1 |
| Association of the Cervical Microbiota With Pregnancy Outcome in a Subfertile Population Undergoing In Vitro Fertilization: A Case-Control Study/Experiment 1/Signature 1 |
| Association of the Cervical Microbiota With Pregnancy Outcome in a Subfertile Population Undergoing In Vitro Fertilization: A Case-Control Study/Experiment 1/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 1/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 1/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 2/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 2/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 3 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 3/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 3/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 4 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 5 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 6 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 6/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 6/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 7 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 8 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 8/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 8/Signature 2 |
| Body site-typical microbiome signatures for children/Experiment 2 |
| Body site-typical microbiome signatures for children/Experiment 2/Signature 1 |
| Body site-typical microbiome signatures for children/Experiment 2/Signature 2 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 1 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 1/Signature 1 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 1/Signature 2 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 2 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 2/Signature 1 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 2/Signature 2 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 3 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 4 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 5 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 5/Signature 1 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 6 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 7 |
| Breast cancer but not the menopausal status is associated with small changes of the gut microbiota/Experiment 8 |
| Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study |
| Changes in the Gut Microbiome and Predicted Functional Metabolic Effects in an Australian Parkinson's Disease Cohort |
| Changes in the Gut Microbiome and Predicted Functional Metabolic Effects in an Australian Parkinson's Disease Cohort/Experiment 1 |
| Changes in the Gut Microbiome and Predicted Functional Metabolic Effects in an Australian Parkinson's Disease Cohort/Experiment 1/Signature 1 |
| Changes in the Gut Microbiome and Predicted Functional Metabolic Effects in an Australian Parkinson's Disease Cohort/Experiment 1/Signature 2 |
| Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome |
| Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome/Experiment 1 |
| Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome/Experiment 1/Signature 1 |
| Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome/Experiment 2 |
| Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome/Experiment 2/Signature 1 |
| Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome/Experiment 2/Signature 2 |
| Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome/Experiment 3 |
| Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome/Experiment 3/Signature 1 |
| Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome/Experiment 4 |
| Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome/Experiment 4/Signature 1 |
| Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome/Experiment 4/Signature 2 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 1 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 2 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 3 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 4 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 4/Signature 1 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 4/Signature 2 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 5 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 5/Signature 1 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 5/Signature 2 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 6 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 6/Signature 1 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 6/Signature 2 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 7 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 8 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 9 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 10 |
| Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma |
| Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma/Experiment 1 |
| Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma/Experiment 1/Signature 1 |
| Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma/Experiment 1/Signature 2 |
| Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma/Experiment 2 |
| Characterization of Supragingival Plaque and Oral Swab Microbiomes in Children With Severe Early Childhood Caries |
| Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes/Experiment 2/Signature 1 |
| Clinical Significance of Composition and Functional Diversity of the Vaginal Microbiome in Recurrent Vaginitis |
| Clinical Significance of Composition and Functional Diversity of the Vaginal Microbiome in Recurrent Vaginitis/Experiment 1 |
| Clinical Significance of Composition and Functional Diversity of the Vaginal Microbiome in Recurrent Vaginitis/Experiment 1/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 1/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 1/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 2/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 2/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 3 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 3/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 3/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 4 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 4/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 4/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 5 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 5/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 5/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 6 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 6/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 6/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 7 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 7/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 7/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 8 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 8/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 8/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 9 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 9/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 10 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 10/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 10/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 11 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 11/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 11/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 12 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 12/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 12/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 13 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 14 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 15 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 15/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 16 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 16/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 16/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 17 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 18 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 19 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 19/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 19/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 20 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 20/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 20/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 21 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 22 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 23 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 23/Signature 1 |
| Comparison of fecal and oral collection methods for studies of the human microbiota in two Iranian cohorts |
| Comparison of fecal and oral collection methods for studies of the human microbiota in two Iranian cohorts/Experiment 1 |
| Comparison of fecal and oral collection methods for studies of the human microbiota in two Iranian cohorts/Experiment 1/Signature 1 |
| Comparison of fecal and oral collection methods for studies of the human microbiota in two Iranian cohorts/Experiment 1/Signature 2 |
| Comparison of fecal and oral collection methods for studies of the human microbiota in two Iranian cohorts/Experiment 2 |
| Comparison of fecal and oral collection methods for studies of the human microbiota in two Iranian cohorts/Experiment 2/Signature 1 |
| Comparison of fecal and oral collection methods for studies of the human microbiota in two Iranian cohorts/Experiment 2/Signature 2 |
| Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls |
| Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls/Experiment 1 |
| Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls/Experiment 1/Signature 1 |
| Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls/Experiment 1/Signature 2 |
| Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls/Experiment 1/Signature 3 |
| Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls/Experiment 1/Signature 4 |
| Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls/Experiment 1/Signature 5 |
| Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls/Experiment 1/Signature 6 |
| Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer |
| Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer/Experiment 1 |
| Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer/Experiment 1/Signature 1 |
| Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer/Experiment 1/Signature 2 |
| Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer/Experiment 2 |
| Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer/Experiment 2/Signature 1 |
| Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer/Experiment 2/Signature 2 |
| Correlation of gut microbiota with leukopenia after chemotherapy in patients with colorectal cancer |
| Correlation of gut microbiota with leukopenia after chemotherapy in patients with colorectal cancer/Experiment 1 |
| Correlation of gut microbiota with leukopenia after chemotherapy in patients with colorectal cancer/Experiment 1/Signature 1 |
| Correlation of gut microbiota with leukopenia after chemotherapy in patients with colorectal cancer/Experiment 2 |
| Correlation of gut microbiota with leukopenia after chemotherapy in patients with colorectal cancer/Experiment 2/Signature 1 |
| Correlation of gut microbiota with leukopenia after chemotherapy in patients with colorectal cancer/Experiment 2/Signature 2 |
| Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease |
| Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease/Experiment 1 |
| Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease/Experiment 1/Signature 1 |
| Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease/Experiment 1/Signature 2 |
| Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease/Experiment 2 |
| Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease/Experiment 2/Signature 1 |
| Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease/Experiment 2/Signature 2 |
| Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease/Experiment 3 |
| Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease/Experiment 3/Signature 1 |
| Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease/Experiment 3/Signature 2 |
| Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease/Experiment 3/Signature 2 |
| Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma/Experiment 1 |
| Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease |
| Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease/Experiment 1 |
| Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease/Experiment 1/Signature 1 |
| Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease/Experiment 1/Signature 2 |
| Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns/Experiment 1 |
| Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 4/Signature 2 |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation/Experiment 1 |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation/Experiment 1/Signature 1 |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation/Experiment 1/Signature 2 |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation/Experiment 2 |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation/Experiment 2/Signature 1 |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation/Experiment 2/Signature 2 |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation/Experiment 3 |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation/Experiment 3/Signature 1 |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation/Experiment 3/Signature 2 |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation/Experiment 4 |
| Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation/Experiment 4/Signature 1 |
| Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe |
| Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe/Experiment 1 |
| Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe/Experiment 1/Signature 1 |
| Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe/Experiment 2 |
| Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe/Experiment 2/Signature 2 |
| Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe/Experiment 3 |
| Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe/Experiment 3/Signature 1 |
| Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe/Experiment 3/Signature 2 |
| Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe/Experiment 4 |
| Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe/Experiment 4/Signature 1 |
| Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe/Experiment 4/Signature 2 |
| Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer |
| Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer/Experiment 1 |
| Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer/Experiment 1/Signature 1 |
| Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer/Experiment 1/Signature 2 |
| Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer/Experiment 2 |
| Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer/Experiment 2/Signature 1 |
| Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer/Experiment 2/Signature 2 |
| Differential peripheral immune signatures elicited by vegan versus ketogenic diets in humans |
| Differential peripheral immune signatures elicited by vegan versus ketogenic diets in humans/Experiment 1 |
| Differential peripheral immune signatures elicited by vegan versus ketogenic diets in humans/Experiment 1/Signature 1 |
| Differential peripheral immune signatures elicited by vegan versus ketogenic diets in humans/Experiment 1/Signature 2 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 1 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 1/Signature 1 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 1/Signature 2 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 2 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 2/Signature 1 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 2/Signature 2 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 3 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 3/Signature 1 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 3/Signature 2 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 4 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 4/Signature 1 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 4/Signature 2 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 5 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 5/Signature 1 |
| Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 5/Signature 2 |
| Disturbed microbial ecology in Alzheimer's disease: evidence from the gut microbiota and fecal metabolome |
| Disturbed microbial ecology in Alzheimer's disease: evidence from the gut microbiota and fecal metabolome/Experiment 1 |
| Disturbed microbial ecology in Alzheimer's disease: evidence from the gut microbiota and fecal metabolome/Experiment 1/Signature 1 |
| Disturbed microbial ecology in Alzheimer's disease: evidence from the gut microbiota and fecal metabolome/Experiment 1/Signature 2 |
| Divergent maturational patterns of the infant bacterial and fungal gut microbiome in the first year of life are associated with inter-kingdom community dynamics and infant nutrition/Experiment 1/Signature 2 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 1 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 1/Signature 1 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 1/Signature 2 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 2 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 2/Signature 1 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 2/Signature 2 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 3 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 3/Signature 1 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 3/Signature 2 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 4 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 4/Signature 1 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 4/Signature 2 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 5 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 5/Signature 1 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 5/Signature 2 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 6 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 6/Signature 1 |
| Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 6/Signature 2 |
| Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients |
| Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients/Experiment 1 |
| Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients/Experiment 1/Signature 1 |
| Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients/Experiment 1/Signature 2 |
| Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients/Experiment 2 |
| Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients/Experiment 2/Signature 1 |
| Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients/Experiment 2/Signature 2 |
| Dysbiosis of gut microbiota in a selected population of Parkinson's patients |
| Dysbiosis of gut microbiota in a selected population of Parkinson's patients/Experiment 1 |
| Dysbiosis of gut microbiota in a selected population of Parkinson's patients/Experiment 1/Signature 1 |
| Dysbiosis of gut microbiota in a selected population of Parkinson's patients/Experiment 1/Signature 2 |
| Dysbiosis of gut microbiota in a selected population of Parkinson's patients/Experiment 2 |
| Dysbiosis of gut microbiota in a selected population of Parkinson's patients/Experiment 2/Signature 1 |
| Dysbiosis of gut microbiota in a selected population of Parkinson's patients/Experiment 2/Signature 2 |
| Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson's disease |
| Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson's disease/Experiment 1 |
| Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson's disease/Experiment 1/Signature 1 |
| Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson's disease/Experiment 1/Signature 2 |
| Dysbiosis of Oral Microbiota and Metabolite Profiles Associated with Type 2 Diabetes Mellitus/Experiment 2/Signature 2 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 1 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 1/Signature 1 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 1/Signature 2 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 2 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 3 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 4 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 4/Signature 1 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 4/Signature 2 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 5 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 5/Signature 1 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 5/Signature 2 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 6 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 7 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 7/Signature 1 |
| Dysbiosis of saliva microbiome in patients with oral lichen planus/Experiment 7/Signature 2 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 1 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 1/Signature 1 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 1/Signature 2 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 2 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 2/Signature 1 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 2/Signature 2 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 3 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 3/Signature 1 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 3/Signature 2 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 4 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 4/Signature 1 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 4/Signature 2 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 5 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 5/Signature 1 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 6 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 6/Signature 1 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 7 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 7/Signature 1 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 8 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 8/Signature 1 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 8/Signature 2 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 9 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 10 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 11 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 12 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 13 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 14 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 15 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 16 |
| Dysbiosis of skin microbiome and gut microbiome in melanoma progression/Experiment 17 |
| Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome |
| Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome/Experiment 1 |
| Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome/Experiment 1/Signature 1 |
| Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome/Experiment 1/Signature 2 |
| Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome/Experiment 2 |
| Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome/Experiment 2/Signature 1 |
| Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome/Experiment 3 |
| Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome/Experiment 3/Signature 1 |
| Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome/Experiment 3/Signature 2 |
| Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome/Experiment 4 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 1 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 1/Signature 1 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 2/Signature 2 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 3/Signature 1 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 3/Signature 2 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 5/Signature 1 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 6/Signature 1 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 7/Signature 1 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 8/Signature 2 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 11/Signature 2 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 12/Signature 1 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 15/Signature 1 |
| Effects of OsomeFood Clean Label plant-based meals on the gut microbiome |
| Effects of OsomeFood Clean Label plant-based meals on the gut microbiome/Experiment 1 |
| Effects of OsomeFood Clean Label plant-based meals on the gut microbiome/Experiment 1/Signature 1 |
| Effects of OsomeFood Clean Label plant-based meals on the gut microbiome/Experiment 1/Signature 2 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome/Experiment 1 |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome/Experiment 1/Signature 1 |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome/Experiment 1/Signature 2 |
| Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 2/Signature 1 |
| Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 4 |
| Enterotype-based Analysis of Gut Microbiota along the Conventional Adenoma-Carcinoma Colorectal Cancer Pathway/Experiment 1/Signature 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 1/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 1/Signature 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 2/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 2/Signature 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 3 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 3/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 3/Signature 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 4 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 5 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 6 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 6/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 6/Signature 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 7 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 7/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 7/Signature 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 8 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 8/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 8/Signature 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 9 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 9/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 10 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 10/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 10/Signature 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 11 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 11/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 11/Signature 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 12 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 12/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 12/Signature 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 13 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 13/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 13/Signature 2 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 14 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 14/Signature 1 |
| Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices/Experiment 14/Signature 2 |
| Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 2/Signature 2 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 1 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 1/Signature 1 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 1/Signature 2 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 2 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 2/Signature 1 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 2/Signature 2 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 3 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 3/Signature 1 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 4 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 4/Signature 1 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 4/Signature 2 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 5 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 5/Signature 1 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 5/Signature 2 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 6 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 6/Signature 1 |
| Exploring gut microbiota in adult Atlantic salmon (Salmo salar L.): Associations with gut health and dietary prebiotics/Experiment 6/Signature 2 |
| Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection |
| Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection/Experiment 1/Signature 1 |
| Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection/Experiment 1/Signature 2 |
| Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection/Experiment 2 |
| Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection/Experiment 2/Signature 1 |
| Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection/Experiment 2/Signature 2 |
| Exploring the alteration of gut microbiota and brain function in gender-specific Parkinson's disease based on metagenomic sequencing |
| Exploring the alteration of gut microbiota and brain function in gender-specific Parkinson's disease based on metagenomic sequencing/Experiment 1 |
| Exploring the alteration of gut microbiota and brain function in gender-specific Parkinson's disease based on metagenomic sequencing/Experiment 1/Signature 1 |
| Exploring the alteration of gut microbiota and brain function in gender-specific Parkinson's disease based on metagenomic sequencing/Experiment 1/Signature 2 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 1 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 1/Signature 1 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 1/Signature 2 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 2 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 3 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 3/Signature 1 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 3/Signature 2 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 4 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 4/Signature 1 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 5 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 5/Signature 1 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 5/Signature 2 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 6 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 6/Signature 1 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 7 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 7/Signature 1 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 7/Signature 2 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 8 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 8/Signature 1 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 9 |
| External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 9/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 1/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 1/Signature 2 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 2 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 2/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 3 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 3/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 4 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 5 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 5/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 6 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 6/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 7 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 7/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 8 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 9 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 9/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 10 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 11 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 12 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 12/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 13 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 13/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 14 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 14/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 15 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 16 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 16/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 17 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 17/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 18 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 18/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 19 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 19/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 20 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 21 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 21/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 22 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 22/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 23 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 23/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 24 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 24/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 25 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 25/Signature 1 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 1 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 1/Signature 1 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 1/Signature 2 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 2 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 2/Signature 1 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 2/Signature 2 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 3 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 3/Signature 1 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 3/Signature 2 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 4 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 4/Signature 1 |
| Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 4/Signature 2 |
| Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis |
| Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis/Experiment 1 |
| Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis/Experiment 1/Signature 1 |
| Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis/Experiment 1/Signature 2 |
| Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis/Experiment 2 |
| Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis/Experiment 2/Signature 1 |
| Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis/Experiment 2/Signature 2 |
| Fusobacteria alterations are associated with colorectal cancer liver metastasis and a poor prognosis/Experiment 1 |
| Fusobacteria alterations are associated with colorectal cancer liver metastasis and a poor prognosis/Experiment 1/Signature 1 |
| Fusobacteria alterations are associated with colorectal cancer liver metastasis and a poor prognosis/Experiment 1/Signature 2 |
| Fusobacteria alterations are associated with colorectal cancer liver metastasis and a poor prognosis/Experiment 2/Signature 2 |
| Fusobacterium is associated with colorectal adenomas |
| Fusobacterium is associated with colorectal adenomas/Experiment 1 |
| Fusobacterium is associated with colorectal adenomas/Experiment 1/Signature 1 |
| Genomic analysis identifies association of Fusobacterium with colorectal carcinoma |
| Genomic analysis identifies association of Fusobacterium with colorectal carcinoma/Experiment 1 |
| Genomic analysis identifies association of Fusobacterium with colorectal carcinoma/Experiment 1/Signature 1 |
| Genomic analysis identifies association of Fusobacterium with colorectal carcinoma/Experiment 1/Signature 2 |
| Genomic analysis identifies association of Fusobacterium with colorectal carcinoma/Experiment 2 |
| Genomic analysis identifies association of Fusobacterium with colorectal carcinoma/Experiment 2/Signature 1 |
| Genomic analysis identifies association of Fusobacterium with colorectal carcinoma/Experiment 2/Signature 2 |
| Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis |
| Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis/Experiment 1 |
| Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis/Experiment 1/Signature 1 |
| Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis/Experiment 1/Signature 2 |
| Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis/Experiment 2 |
| Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis/Experiment 2/Signature 1 |
| Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis/Experiment 2/Signature 2 |
| Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis/Experiment 3 |
| Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis/Experiment 3/Signature 1 |
| Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis/Experiment 3/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 1/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 1/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 2/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 2/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 3 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 3/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 3/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 4 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 4/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 4/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 5 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 5/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 5/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 6 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 6/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 6/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 7 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 7/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 7/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 8 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 8/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 8/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 9 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 9/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 10 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 10/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 10/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 1/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 1/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 2/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 2/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 3 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 3/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 3/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 4 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 4/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 4/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 5 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 5/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 5/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 6 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 6/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 6/Signature 2 |
| Gut microbiome and atrial fibrillation-results from a large population-based study/Experiment 3/Signature 1 |
| Gut microbiome and atrial fibrillation-results from a large population-based study/Experiment 3/Signature 2 |
| Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 5 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 3 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 4 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 5 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 6 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 1 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 1/Signature 1 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 1/Signature 2 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 2 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 2/Signature 1 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 2/Signature 2 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 3 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 3/Signature 1 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 4 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 4/Signature 1 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 5 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 5/Signature 1 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 6 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 6/Signature 1 |
| Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition/Experiment 6/Signature 2 |
| Gut microbiota are related to Parkinson's disease and clinical phenotype/Experiment 1/Signature 2 |
| Gut Microbiota Associated with Clinical Relapse in Patients with Quiescent Ulcerative Colitis/Experiment 2/Signature 2 |
| Gut microbiota diversity across ethnicities in the United States/Experiment 6/Signature 1 |
| Gut microbiota diversity across ethnicities in the United States/Experiment 6/Signature 2 |
| Gut Microbiota Dysbiosis Induced by Decreasing Endogenous Melatonin Mediates the Pathogenesis of Alzheimer's Disease and Obesity |
| Gut Microbiota Dysbiosis Induced by Decreasing Endogenous Melatonin Mediates the Pathogenesis of Alzheimer's Disease and Obesity/Experiment 1 |
| Gut Microbiota Dysbiosis Induced by Decreasing Endogenous Melatonin Mediates the Pathogenesis of Alzheimer's Disease and Obesity/Experiment 1/Signature 1 |
| Gut Microbiota Dysbiosis Induced by Decreasing Endogenous Melatonin Mediates the Pathogenesis of Alzheimer's Disease and Obesity/Experiment 1/Signature 2 |
| Gut Microbiota is Altered in Patients with Alzheimer's Disease/Experiment 1/Signature 2 |
| Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease/Experiment 2/Signature 1 |
| Gut microbiota-associated taurine metabolism dysregulation in a mouse model of Parkinson's disease |
| Gut microbiota-associated taurine metabolism dysregulation in a mouse model of Parkinson's disease/Experiment 1 |
| Gut microbiota-associated taurine metabolism dysregulation in a mouse model of Parkinson's disease/Experiment 1/Signature 1 |
| Gut microbiota-associated taurine metabolism dysregulation in a mouse model of Parkinson's disease/Experiment 1/Signature 2 |
| Gut microbiota: effect of pubertal status |
| Gut microbiota: effect of pubertal status/Experiment 1 |
| Gut microbiota: effect of pubertal status/Experiment 1/Signature 1 |
| Gut microbiota: effect of pubertal status/Experiment 1/Signature 2 |
| Gut microbiota: impacts on gastrointestinal cancer immunotherapy/Experiment 1/Signature 2 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 1 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 2 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 3 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 4 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 5 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 6 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 7 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 8 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 8/Signature 1 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 8/Signature 2 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 9 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 9/Signature 1 |
| Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host/Experiment 9/Signature 2 |
| Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 1/Signature 1 |
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome |
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 1 |
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 1/Signature 2 |
| HIV-Positive Patients on Antiretroviral Therapy Have an Altered Mucosal Intestinal but Not Oral Microbiome |
| HIV-Positive Patients on Antiretroviral Therapy Have an Altered Mucosal Intestinal but Not Oral Microbiome/Experiment 1 |
| HIV-Positive Patients on Antiretroviral Therapy Have an Altered Mucosal Intestinal but Not Oral Microbiome/Experiment 1/Signature 1 |
| HIV-Positive Patients on Antiretroviral Therapy Have an Altered Mucosal Intestinal but Not Oral Microbiome/Experiment 1/Signature 2 |
| Household environment and animal fecal contamination are critical modifiers of the gut microbiome and resistome in young children from rural Nicaragua |
| Household environment and animal fecal contamination are critical modifiers of the gut microbiome and resistome in young children from rural Nicaragua/Experiment 1 |
| Household environment and animal fecal contamination are critical modifiers of the gut microbiome and resistome in young children from rural Nicaragua/Experiment 1/Signature 1 |
| Household environment and animal fecal contamination are critical modifiers of the gut microbiome and resistome in young children from rural Nicaragua/Experiment 1/Signature 2 |
| Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats |
| Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats/Experiment 1 |
| Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats/Experiment 1/Signature 1 |
| Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats/Experiment 1/Signature 2 |
| Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats/Experiment 2 |
| Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats/Experiment 2/Signature 1 |
| Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats/Experiment 2/Signature 2 |
| Immunoregulatory role of the gut microbiota in inflammatory depression |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 1 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 1/Signature 1 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 2 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 2/Signature 1 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 3 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 3/Signature 1 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 4 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 4/Signature 1 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 4/Signature 2 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 5 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 5/Signature 1 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 6 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 6/Signature 1 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 7 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 7/Signature 1 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 7/Signature 2 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 8 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 8/Signature 1 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 8/Signature 2 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 9 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 9/Signature 1 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 9/Signature 2 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 10 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 10/Signature 1 |
| Immunoregulatory role of the gut microbiota in inflammatory depression/Experiment 10/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 1/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 1/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 2/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 2/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 3 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 3/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 3/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 4 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 4/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 4/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 5 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 5/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 5/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 6 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 6/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 6/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 7 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 7/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 7/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 8 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 8/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 8/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 9 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 9/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 9/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 10 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 10/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 10/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 11 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 11/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 11/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 12 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 12/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 12/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 13 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 13/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 13/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 14 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 14/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 14/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 15 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 15/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 15/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 16 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 16/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 16/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 17 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 17/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 17/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 18 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 18/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 18/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 19 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 19/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 19/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 20 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 20/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 20/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 21 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 21/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 21/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 22 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 23 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 24 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 25 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 25/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 25/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 26 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 26/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 26/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 27 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 27/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 27/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 28 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 28/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 28/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 29 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 29/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 29/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 30 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 30/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 30/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 31 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 31/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 31/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 32 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 32/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 32/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 33 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 33/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 33/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 34 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 34/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 34/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 35 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 35/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 35/Signature 2 |
| Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring/Experiment 2 |
| Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring/Experiment 3 |
| Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring/Experiment 3/Signature 1 |
| Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring/Experiment 3/Signature 2 |
| Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring/Experiment 4 |
| Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring/Experiment 4/Signature 1 |
| Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring/Experiment 4/Signature 2 |
| Implications of gut microbiota dysbiosis and metabolic changes in prion disease |
| Implications of gut microbiota dysbiosis and metabolic changes in prion disease/Experiment 1 |
| Implications of gut microbiota dysbiosis and metabolic changes in prion disease/Experiment 1/Signature 1 |
| Implications of gut microbiota dysbiosis and metabolic changes in prion disease/Experiment 1/Signature 2 |
| Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1 |
| Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans |
| Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans/Experiment 1 |
| Inflammatory cytokines IL-6, IL-10, IL-13, TNF-α and peritoneal fluid flora were associated with infertility in patients with endometriosis/Experiment 1 |
| Influence of cigarette smoking on the human duodenal mucosa-associated microbiota |
| Influence of cigarette smoking on the human duodenal mucosa-associated microbiota/Experiment 2 |
| Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease |
| Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease/Experiment 1 |
| Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease/Experiment 2 |
| Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease/Experiment 3 |
| Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease/Experiment 3/Signature 1 |
| Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease/Experiment 3/Signature 2 |
| Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease/Experiment 4 |
| Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease/Experiment 5 |
| Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease/Experiment 6 |
| Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease/Experiment 6/Signature 1 |
| Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease/Experiment 6/Signature 2 |
| Insights into estrogen impact in oral health & microbiome in COVID-19 |
| Insights into estrogen impact in oral health & microbiome in COVID-19/Experiment 1 |
| Insights into estrogen impact in oral health & microbiome in COVID-19/Experiment 1/Signature 1 |
| Insights into estrogen impact in oral health & microbiome in COVID-19/Experiment 1/Signature 2 |
| Insights into estrogen impact in oral health & microbiome in COVID-19/Experiment 2 |
| Insights into estrogen impact in oral health & microbiome in COVID-19/Experiment 2/Signature 1 |
| Insights into estrogen impact in oral health & microbiome in COVID-19/Experiment 2/Signature 2 |
| Insights into estrogen impact in oral health & microbiome in COVID-19/Experiment 3 |
| Insights into estrogen impact in oral health & microbiome in COVID-19/Experiment 3/Signature 1 |
| Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing |
| Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing/Experiment 1 |
| Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing/Experiment 1/Signature 1 |
| Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing/Experiment 1/Signature 2 |
| Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing/Experiment 2 |
| Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing/Experiment 2/Signature 1 |
| Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing/Experiment 2/Signature 2 |
| Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing/Experiment 3 |
| Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing/Experiment 3/Signature 1 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 1 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 1/Signature 1 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 1/Signature 2 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 2 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 2/Signature 1 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 3 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 3/Signature 1 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 3/Signature 2 |
| Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 1 |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 1/Signature 1 |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 2 |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 2/Signature 1 |
| Interaction between Cervical Microbiota and Host Gene Regulation in Caesarean Section Scar Diverticulum |
| Interaction between Cervical Microbiota and Host Gene Regulation in Caesarean Section Scar Diverticulum/Experiment 1 |
| Interaction between Cervical Microbiota and Host Gene Regulation in Caesarean Section Scar Diverticulum/Experiment 1/Signature 1 |
| Interaction between Cervical Microbiota and Host Gene Regulation in Caesarean Section Scar Diverticulum/Experiment 1/Signature 2 |
| Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease |
| Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 4 |
| Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 5 |
| Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 6 |
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 1 |
| Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment |
| Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 1 |
| Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 1/Signature 1 |
| Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 1/Signature 2 |
| Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 2 |
| Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 2/Signature 1 |
| Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 2/Signature 2 |
| Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 3 |
| Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 3/Signature 1 |
| Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 3/Signature 2 |
| Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 4 |
| Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 3 |
| Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 3/Signature 2 |
| Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics |
| Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 1 |
| Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 1/Signature 1 |
| Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 1/Signature 2 |
| Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 2 |
| Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 2/Signature 1 |
| Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 2/Signature 2 |
| Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 3 |
| Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 3/Signature 1 |
| Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 3/Signature 2 |
| Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity/Experiment 1 |
| Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity/Experiment 3 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 1/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 1/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 2 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 2/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 2/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 3 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 3/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 3/Signature 2 |
| Learning machine approach reveals microbial signatures of diet and sex in dog/Experiment 2/Signature 2 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 1 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 1/Signature 1 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 1/Signature 2 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 2 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 2/Signature 1 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 2/Signature 2 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 3 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 3/Signature 1 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 3/Signature 2 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 4 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 4/Signature 1 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 4/Signature 2 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 5 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 5/Signature 1 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 5/Signature 2 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 6 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 6/Signature 1 |
| Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients/Experiment 6/Signature 2 |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1 |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1/Signature 1 |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1/Signature 2 |
| Linking long-term dietary patterns with gut microbial enterotypes |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 1 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 2 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 1 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 2 |
| Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 1 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 2 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 2/Signature 1 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 2/Signature 2 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 3 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 4 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 5 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 6 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 7 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 7/Signature 1 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 7/Signature 2 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 8 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 9 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 10 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 11 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 11/Signature 1 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 11/Signature 2 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 12 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 12/Signature 1 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 13 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 13/Signature 1 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 13/Signature 2 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 14 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 14/Signature 1 |
| Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection/Experiment 14/Signature 2 |
| Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 7/Signature 1 |
| Longitudinal gut microbiota composition of South African and Nigerian infants in relation to tetanus vaccine responses |
| Longitudinal gut microbiota composition of South African and Nigerian infants in relation to tetanus vaccine responses/Experiment 1 |
| Longitudinal gut microbiota composition of South African and Nigerian infants in relation to tetanus vaccine responses/Experiment 1/Signature 1 |
| Longitudinal gut microbiota composition of South African and Nigerian infants in relation to tetanus vaccine responses/Experiment 1/Signature 2 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 1 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 1/Signature 1 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 1/Signature 2 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 2 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 2/Signature 1 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 2/Signature 2 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 3 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 3/Signature 1 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 3/Signature 2 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 4 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 4/Signature 1 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 4/Signature 2 |
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1 |
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1/Signature 1 |
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1/Signature 2 |
| Major urinary protein (Mup) gene family deletion drives sex-specific alterations on the house mouse gut microbiota/Experiment 1 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 1/Signature 1 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 2 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 2/Signature 1 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 2/Signature 2 |
| Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles |
| Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 1 |
| Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 1/Signature 1 |
| Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 2 |
| Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 2/Signature 1 |
| Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 3 |
| Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 4 |
| Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 5 |
| Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 5/Signature 1 |
| Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 6 |
| Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 6/Signature 1 |
| Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery/Experiment 2/Signature 1 |
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 1 |
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 2 |
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 3 |
| Metabolic disorder and intestinal microflora dysbiosis in chronic inflammatory demyelinating polyradiculoneuropathy |
| Metabolic disorder and intestinal microflora dysbiosis in chronic inflammatory demyelinating polyradiculoneuropathy/Experiment 1 |
| Metabolic disorder and intestinal microflora dysbiosis in chronic inflammatory demyelinating polyradiculoneuropathy/Experiment 1/Signature 1 |
| Metabolic disorder and intestinal microflora dysbiosis in chronic inflammatory demyelinating polyradiculoneuropathy/Experiment 1/Signature 2 |
| Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation/Experiment 1 |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese/Experiment 1 |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese/Experiment 1/Signature 1 |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease/Experiment 1 |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease/Experiment 1/Signature 1 |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease/Experiment 1/Signature 2 |
| Microbial communities associated with honey bees in Brazil and in the United States |
| Microbial communities associated with honey bees in Brazil and in the United States/Experiment 1 |
| Microbial communities associated with honey bees in Brazil and in the United States/Experiment 1/Signature 1 |
| Microbial communities associated with honey bees in Brazil and in the United States/Experiment 1/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 1/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 1/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 2/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 2/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 3 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 3/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 3/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 4 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 4/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 4/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 5 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 5/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 5/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 6 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 6/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 6/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 7 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 7/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 7/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 8 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 8/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 8/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 9 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 9/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 9/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 10 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 10/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 10/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 11 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 11/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 11/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 12 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 12/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 12/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 13 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 13/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 13/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 14 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 14/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 14/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 15 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 15/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 15/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 16 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 17 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 18 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 19 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 20 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 21 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 22 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 23 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 24 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 25 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 26 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 27 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 28 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 29 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 30 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 31 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 32 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 33 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 34 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 35 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 36 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 37 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 38 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 39 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 40 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 41 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 42 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 43 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 44 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 45 |
| Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice |
| Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice/Experiment 1/Signature 1 |
| Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice/Experiment 1/Signature 2 |
| Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice/Experiment 1/Signature 3 |
| Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice/Experiment 1/Signature 4 |
| Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice/Experiment 1/Signature 5 |
| Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice/Experiment 1/Signature 6 |
| Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice/Experiment 1/Signature 7 |
| Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice/Experiment 2 |
| Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice/Experiment 2/Signature 1 |
| Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice/Experiment 2/Signature 2 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 1/Signature 3 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2/Signature 1 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2/Signature 2 |
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1 |
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1/Signature 1 |
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1/Signature 2 |
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 2 |
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 2/Signature 1 |
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 2/Signature 2 |
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 4 |
| Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment |
| Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment/Experiment 1 |
| Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment/Experiment 1/Signature 1 |
| Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment/Experiment 1/Signature 2 |
| Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment/Experiment 2 |
| Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment/Experiment 2/Signature 1 |
| Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment/Experiment 3 |
| Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment/Experiment 3/Signature 1 |
| Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment/Experiment 4 |
| Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment/Experiment 4/Signature 1 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 1 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 1/Signature 1 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 1/Signature 2 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 2 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 2/Signature 1 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 2/Signature 2 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 3 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 3/Signature 1 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 4 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 4/Signature 1 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 4/Signature 2 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 5 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 5/Signature 1 |
| Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System/Experiment 5/Signature 2 |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1 |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1/Signature 1 |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1/Signature 2 |
| More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota |
| More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota/Experiment 1 |
| More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota/Experiment 1/Signature 1 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 1 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 2 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 3 |
| Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients |
| Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients/Experiment 1 |
| Normal gut microbiome in NMDA receptor encephalitis |
| Normal gut microbiome in NMDA receptor encephalitis/Experiment 1 |
| Normal gut microbiome in NMDA receptor encephalitis/Experiment 1/Signature 1 |
| Normal gut microbiome in NMDA receptor encephalitis/Experiment 1/Signature 2 |
| Nutritional Intake and Gut Microbiome Composition Predict Parkinson's Disease/Experiment 1/Signature 1 |
| Nutritional Intake and Gut Microbiome Composition Predict Parkinson's Disease/Experiment 1/Signature 2 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 1 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 1/Signature 1 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 1/Signature 2 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 2 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 2/Signature 1 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 2/Signature 2 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 3 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 3/Signature 1 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 3/Signature 2 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 4 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 4/Signature 1 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 4/Signature 2 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 5 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 5/Signature 1 |
| Oral and gut dysbiosis leads to functional alterations in Parkinson's disease/Experiment 5/Signature 2 |
| Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients |
| Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 1 |
| Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 1/Signature 1 |
| Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 1/Signature 2 |
| Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 2 |
| Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 2/Signature 1 |
| Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 2/Signature 2 |
| Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 3 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 1/Signature 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 2 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 2/Signature 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 3 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 3/Signature 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 4 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 4/Signature 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 5 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 5/Signature 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 5/Signature 2 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 6 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 6/Signature 1 |
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2 |
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2/Signature 1 |
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2/Signature 2 |
| Oral microbiome and obesity in a large study of low-income and African-American populations |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 1 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 1/Signature 1 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2/Signature 1 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2/Signature 2 |
| Oral microbiome and preterm birth |
| Oral microbiome and preterm birth/Experiment 1 |
| Oral microbiome and preterm birth/Experiment 1/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 1/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 1/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 2/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 2/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 3 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 3/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 3/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 4 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 4/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 4/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 5 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 5/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 5/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 6 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 6/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 6/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 7 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 7/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 7/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 8 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 8/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 8/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 9 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 9/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 9/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 10 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 10/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 10/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 11 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 11/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 12 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 12/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 12/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 13 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 13/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 13/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 14 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 14/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 14/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 15 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 15/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 15/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 16 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 16/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 16/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 17 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 17/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 17/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 18 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 18/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 18/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 19 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 19/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 19/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 20 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 20/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 21 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 21/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 21/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 22 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 22/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 22/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 23 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 23/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 24 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 24/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 24/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 25 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 25/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 26 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 26/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 26/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 27 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 27/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 27/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 28 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 28/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 28/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 29 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 29/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 29/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 30 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 30/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 30/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 31 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 31/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 31/Signature 2 |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1 |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1/Signature 1 |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1/Signature 2 |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1 |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1/Signature 1 |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1/Signature 2 |
| Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome/Experiment 1/Signature 1 |
| Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome/Experiment 1/Signature 2 |
| Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome/Experiment 2/Signature 1 |
| Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome/Experiment 2/Signature 2 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 1 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 1/Signature 1 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 1/Signature 2 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 2 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 2/Signature 1 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 2/Signature 2 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 3 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 3/Signature 1 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 4 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 4/Signature 1 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 4/Signature 2 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 5 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 5/Signature 1 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 5/Signature 2 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 6 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 6/Signature 1 |
| Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats/Experiment 6/Signature 2 |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1 |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1/Signature 1 |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1/Signature 2 |
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder |
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder/Experiment 1 |
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder/Experiment 1/Signature 1 |
| Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients/Experiment 3/Signature 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1/Signature 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1/Signature 2 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2/Signature 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2/Signature 2 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 1 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 1/Signature 1 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 2 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 2/Signature 1 |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1 |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 1 |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 2 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1/Signature 1 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1/Signature 2 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2/Signature 1 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2/Signature 2 |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1 |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1/Signature 1 |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1/Signature 2 |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1 |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1/Signature 1 |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1/Signature 2 |
| Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 2 |
| Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease |
| Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease/Experiment 1 |
| Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease/Experiment 1/Signature 1 |
| Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease/Experiment 1/Signature 2 |
| Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease/Experiment 2 |
| Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease/Experiment 2/Signature 1 |
| Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease/Experiment 3 |
| Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease/Experiment 3/Signature 1 |
| Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease/Experiment 3/Signature 2 |
| Profiling the urinary microbiome in men with calcium-based kidney stones |
| Profiling the urinary microbiome in men with calcium-based kidney stones/Experiment 1 |
| Profiling the urinary microbiome in men with calcium-based kidney stones/Experiment 1/Signature 1 |
| Profiling the urinary microbiome in men with calcium-based kidney stones/Experiment 1/Signature 2 |
| Profiling the urinary microbiome in men with calcium-based kidney stones/Experiment 2 |
| Profiling the urinary microbiome in men with calcium-based kidney stones/Experiment 2/Signature 1 |
| Profiling the urinary microbiome in men with calcium-based kidney stones/Experiment 2/Signature 2 |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China/Experiment 1 |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China/Experiment 1/Signature 1 |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China/Experiment 1/Signature 2 |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China/Experiment 2 |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China/Experiment 2/Signature 1 |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China/Experiment 2/Signature 2 |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China/Experiment 3 |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China/Experiment 3/Signature 1 |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China/Experiment 3/Signature 2 |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China/Experiment 4 |
| Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China/Experiment 5 |
| Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study |
| Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study/Experiment 1 |
| Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study/Experiment 1/Signature 1 |
| Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study/Experiment 2 |
| Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study/Experiment 2/Signature 1 |
| Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study/Experiment 3 |
| Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study/Experiment 3/Signature 1 |
| Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study/Experiment 4 |
| Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study/Experiment 4/Signature 1 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 1 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 1/Signature 1 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 1/Signature 2 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 2 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 2/Signature 1 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 2/Signature 2 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 3 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 3/Signature 1 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 3/Signature 2 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 4 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 4/Signature 1 |
| Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia/Experiment 4/Signature 2 |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1 |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1/Signature 1 |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1/Signature 2 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 1/Signature 1 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 1/Signature 2 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2/Signature 1 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2/Signature 2 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3/Signature 1 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3/Signature 2 |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1 |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1/Signature 1 |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1/Signature 2 |
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children |
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children/Experiment 1 |
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children/Experiment 1/Signature 1 |
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1 |
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1/Signature 1 |
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1/Signature 2 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 1 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 1/Signature 1 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 1/Signature 2 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 2 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 2/Signature 1 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 2/Signature 2 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1/Signature 1 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1/Signature 2 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 2 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 2/Signature 1 |
| Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease/Experiment 1/Signature 2 |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1 |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1/Signature 1 |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1/Signature 2 |
| Reduced microbiome alpha diversity in young patients with ADHD |
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1 |
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1/Signature 1 |
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1/Signature 2 |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1 |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1/Signature 1 |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1/Signature 2 |
| Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease |
| Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease/Experiment 1 |
| Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study/Experiment 1/Signature 2 |
| Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study/Experiment 2 |
| Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study/Experiment 2/Signature 1 |
| Resilience of the respiratory microbiome in controlled adult RSV challenge study |
| Resilience of the respiratory microbiome in controlled adult RSV challenge study/Experiment 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1/Signature 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1/Signature 2 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2/Signature 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2/Signature 2 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3/Signature 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3/Signature 2 |
| Role of intestinal flora in the development of nonalcoholic fatty liver disease in children |
| Role of intestinal flora in the development of nonalcoholic fatty liver disease in children/Experiment 1 |
| Role of intestinal flora in the development of nonalcoholic fatty liver disease in children/Experiment 1/Signature 1 |
| Role of intestinal flora in the development of nonalcoholic fatty liver disease in children/Experiment 1/Signature 2 |
| Role of intestinal flora in the development of nonalcoholic fatty liver disease in children/Experiment 2 |
| Role of intestinal flora in the development of nonalcoholic fatty liver disease in children/Experiment 2/Signature 1 |
| Role of intestinal flora in the development of nonalcoholic fatty liver disease in children/Experiment 2/Signature 2 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 1 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 1/Signature 3 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 1/Signature 4 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 2 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 2/Signature 1 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 2/Signature 2 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 3 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 3/Signature 3 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 3/Signature 4 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 4 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 4/Signature 1 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 4/Signature 2 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 5 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 5/Signature 1 |
| Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer/Experiment 5/Signature 2 |
| Salivary microbiome profiles for different clinical phenotypes of pituitary adenomas by single-molecular long-read sequencing |
| Salivary microbiome profiles for different clinical phenotypes of pituitary adenomas by single-molecular long-read sequencing/Experiment 1 |
| Salivary microbiome profiles for different clinical phenotypes of pituitary adenomas by single-molecular long-read sequencing/Experiment 1/Signature 1 |
| Salivary microbiome profiles for different clinical phenotypes of pituitary adenomas by single-molecular long-read sequencing/Experiment 1/Signature 2 |
| SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition |
| SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition/Experiment 1 |
| SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 2/Signature 2 |
| Sex, health status and habitat alter the community composition and assembly processes of symbiotic bacteria in captive frogs |
| Sex, health status and habitat alter the community composition and assembly processes of symbiotic bacteria in captive frogs/Experiment 1 |
| Sex, health status and habitat alter the community composition and assembly processes of symbiotic bacteria in captive frogs/Experiment 1/Signature 1 |
| Sex, health status and habitat alter the community composition and assembly processes of symbiotic bacteria in captive frogs/Experiment 1/Signature 2 |
| Sex, health status and habitat alter the community composition and assembly processes of symbiotic bacteria in captive frogs/Experiment 2 |
| Sex, health status and habitat alter the community composition and assembly processes of symbiotic bacteria in captive frogs/Experiment 2/Signature 1 |
| Sex, health status and habitat alter the community composition and assembly processes of symbiotic bacteria in captive frogs/Experiment 2/Signature 2 |
| Sex-specific differences in intestinal microbiota associated with cardiovascular diseases/Experiment 2/Signature 1 |
| Sex-specific differences in intestinal microbiota associated with cardiovascular diseases/Experiment 2/Signature 2 |
| Shift in skin microbiota of Western European women across aging |
| Shift in skin microbiota of Western European women across aging/Experiment 1 |
| Shift in skin microbiota of Western European women across aging/Experiment 1/Signature 1 |
| Shift in skin microbiota of Western European women across aging/Experiment 1/Signature 2 |
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1 |
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1/Signature 1 |
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1/Signature 2 |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1 |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1/Signature 1 |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1/Signature 2 |
| Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder |
| Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder/Experiment 1 |
| Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder/Experiment 1/Signature 1 |
| Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder/Experiment 1/Signature 2 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 1 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 1/Signature 1 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 1/Signature 2 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 2 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 3 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 4 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 5 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 6 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 7 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 8 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 9 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 10 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 11 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 12 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 13 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 14 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 15 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 16 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 17 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 18 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 19 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 20 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 21 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 22 |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1 |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1/Signature 1 |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1/Signature 2 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1/Signature 1 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1/Signature 2 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 2 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 2/Signature 1 |
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2Â months is associated with a lower risk of atopic dermatitis at 1Â year |
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2Â months is associated with a lower risk of atopic dermatitis at 1Â year/Experiment 1 |
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2Â months is associated with a lower risk of atopic dermatitis at 1Â year/Experiment 1/Signature 1 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 1 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 1/Signature 1 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 1/Signature 2 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 2 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 2/Signature 1 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 2/Signature 2 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 3 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 3/Signature 1 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 3/Signature 2 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 4 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 4/Signature 1 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 4/Signature 2 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 5 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 5/Signature 1 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 5/Signature 2 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 6 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 6/Signature 1 |
| Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites/Experiment 6/Signature 2 |
| Social isolation induces intestinal barrier disorder and imbalances gut microbiota in mice |
| Social isolation induces intestinal barrier disorder and imbalances gut microbiota in mice/Experiment 1 |
| Social isolation induces intestinal barrier disorder and imbalances gut microbiota in mice/Experiment 2 |
| Social isolation induces intestinal barrier disorder and imbalances gut microbiota in mice/Experiment 2/Signature 1 |
| Social isolation induces intestinal barrier disorder and imbalances gut microbiota in mice/Experiment 2/Signature 2 |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1 |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1/Signature 1 |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1/Signature 2 |
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 4 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 1 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 1/Signature 1 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 1/Signature 2 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 2 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 2/Signature 1 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 2/Signature 2 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 3 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 3/Signature 1 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 4 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 4/Signature 1 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 5 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 5/Signature 1 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 6 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 6/Signature 1 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 6/Signature 2 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 7 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 7/Signature 1 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 7/Signature 2 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 8 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 8/Signature 1 |
| Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle/Experiment 8/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 3 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 4 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 5 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 6 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 7 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 8 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 9 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 10 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 11 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 12 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 13 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 14 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 15 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 16 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 17 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 18 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 19 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 20 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 21 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 22 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 23 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 24 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 25 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 26 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 27 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 28 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 29 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 30 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 31 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 32 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 33 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 33/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 33/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 34 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 34/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 34/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 35 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 35/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 35/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 36 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 36/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 36/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 37 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 37/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 37/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 38 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 38/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 38/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 39 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 39/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 39/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 40 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 40/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 40/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 41 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 41/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 41/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 42 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 42/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 42/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 43 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 43/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 43/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 44 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 44/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 44/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 45 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 45/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 45/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 46 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 46/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 46/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 47 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 47/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 47/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 48 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 48/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 48/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 49 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 49/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 49/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 50 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 50/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 50/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 51 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 51/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 51/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 52 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 52/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 52/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 53 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 53/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 53/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 54 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 54/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 54/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 55 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 55/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 55/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 56 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 56/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 56/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 57 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 57/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 57/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 58 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 58/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 58/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 59 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 60 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 61 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 62 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 62/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 62/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 63 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 64 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 64/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 64/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 65 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 65/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 65/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 66 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 66/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 66/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 67 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 67/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 67/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 68 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 68/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 68/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 69 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 69/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 69/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 70 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 70/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 70/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 71 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 71/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 71/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 72 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 72/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 72/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 73 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 74 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 75 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 76 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 77 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 78 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 79 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 80 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 81 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 82 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 83 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 84 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 85 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 86 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 87 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 88 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 89 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 90 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 91 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 92 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 93 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 94 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 95 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 96 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 97 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 98 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 99 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 100 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 101 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 102 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 103 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 104 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 105 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 106 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 107 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 108 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 109 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 109/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 109/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 110 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 110/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 110/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 111 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 111/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 111/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 112 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 112/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 112/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 113 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 113/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 113/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 114 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 114/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 114/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 115 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 115/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 115/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 116 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 116/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 116/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 117 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 117/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 117/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 118 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 118/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 118/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 119 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 119/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 119/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 120 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 120/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 120/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 121 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 121/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 121/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 122 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 122/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 122/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 123 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 123/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 123/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 124 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 124/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 124/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 125 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 125/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 125/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 126 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 126/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 126/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 127 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 127/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 127/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 128 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 128/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 128/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 129 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 129/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 129/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 130 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 130/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 130/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 131 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 131/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 131/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 132 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 132/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 132/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 133 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 133/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 133/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 134 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 134/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 134/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 135 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 135/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 135/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 136 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 136/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 136/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 137 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 137/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 137/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 138 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 138/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 138/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 139 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 139/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 139/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 140 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 140/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 140/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 141 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 141/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 141/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 142 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 142/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 142/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 143 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 143/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 143/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 144 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 144/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 144/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 145 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 145/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 145/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 146 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 146/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 146/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 147 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 147/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 147/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 148 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 148/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 148/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 149 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 149/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 149/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 150 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 150/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 150/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 151 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 151/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 151/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 152 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 152/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 152/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 153 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 153/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 153/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 154 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 154/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 154/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 155 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 155/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 155/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 156 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 156/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 156/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 157 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 157/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 157/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 158 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 158/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 158/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 159 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 159/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 159/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 160 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 160/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 160/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 161 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 162 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 163 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 164 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 165 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 166 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 167 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 168 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 169 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 170 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 171 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 172 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 173 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 174 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 175 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 176 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 177 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 178 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 179 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 180 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 181 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 182 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 183 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 184 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 185 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 186 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 187 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 188 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 189 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 190 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 191 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 192 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 193 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 194 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 195 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 196 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 197 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 198 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 199 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 200 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 201 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 202 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 203 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 204 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 205 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 206 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 207 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 207/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 207/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 208 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 210 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 211 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 212 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 213 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 214 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 215 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 216 |
| Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults/Experiment 1 |
| Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 3/Signature 1 |
| Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features |
| Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features/Experiment 1 |
| Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features/Experiment 1/Signature 1 |
| Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features/Experiment 1/Signature 2 |
| Study 501 |
| Study 501/Experiment 1 |
| Study 501/Experiment 1/Signature 1 |
| Study 783 |
| Study 919/Experiment 1 |
| Study 919/Experiment 1/Signature 1 |
| Study 919/Experiment 1/Signature 2 |
| Study 1018 |
| Study 1018/Experiment 1 |
| Study 1018/Experiment 1/Signature 1 |
| Study 1018/Experiment 1/Signature 2 |
| Study 1067 |
| Study 1067/Experiment 1 |
| Study 1067/Experiment 1/Signature 1 |
| Study 1067/Experiment 1/Signature 2 |
| Study of gut microbiota alterations in Alzheimer's dementia patients from Kazakhstan |
| Study of gut microbiota alterations in Alzheimer's dementia patients from Kazakhstan/Experiment 1 |
| Study of gut microbiota alterations in Alzheimer's dementia patients from Kazakhstan/Experiment 1/Signature 1 |
| Study of gut microbiota alterations in Alzheimer's dementia patients from Kazakhstan/Experiment 1/Signature 2 |
| Study of gut microbiota alterations in Alzheimer's dementia patients from Kazakhstan/Experiment 2 |
| Study of gut microbiota alterations in Alzheimer's dementia patients from Kazakhstan/Experiment 2/Signature 1 |
| Study of gut microbiota alterations in Alzheimer's dementia patients from Kazakhstan/Experiment 2/Signature 2 |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1 |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1/Signature 1 |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1/Signature 2 |
| Subgingival Microbial Changes During the First 3Â Months of Fixed Appliance Treatment in Female Adult Patients |
| Subgingival Microbial Changes During the First 3Â Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 1 |
| Subgingival Microbial Changes During the First 3Â Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 1/Signature 1 |
| Subgingival Microbial Changes During the First 3Â Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2/Signature 1 |
| Subgingival Microbial Changes During the First 3Â Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2/Signature 2 |
| Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 2/Signature 2 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3/Signature 1 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3/Signature 2 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4/Signature 1 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4/Signature 2 |
| Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease/Experiment 2/Signature 1 |
| Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 7 |
| Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 7/Signature 1 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 1 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 2 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 3 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 4 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 5 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 6 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 7 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 1 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 2 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 3 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 4 |
| The adult microbiome of healthy and otitis patients: Definition of the core healthy and diseased ear microbiomes |
| The adult microbiome of healthy and otitis patients: Definition of the core healthy and diseased ear microbiomes/Experiment 1 |
| The adult microbiome of healthy and otitis patients: Definition of the core healthy and diseased ear microbiomes/Experiment 2 |
| The aging mouse microbiome has obesogenic characteristics/Experiment 3/Signature 1 |
| The Airway Microbiota Signatures of Infection and Rejection in Lung Transplant Recipients/Experiment 2/Signature 1 |
| The Airway Microbiota Signatures of Infection and Rejection in Lung Transplant Recipients/Experiment 3/Signature 1 |
| The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease |
| The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease/Experiment 1 |
| The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease/Experiment 1/Signature 1 |
| The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease/Experiment 1/Signature 2 |
| The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease/Experiment 2 |
| The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease/Experiment 2/Signature 1 |
| The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease/Experiment 2/Signature 2 |
| The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease/Experiment 3 |
| The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota |
| The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota/Experiment 1 |
| The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota/Experiment 2 |
| The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota/Experiment 3 |
| The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota/Experiment 4 |
| The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota/Experiment 4/Signature 1 |
| The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota/Experiment 4/Signature 2 |
| The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota/Experiment 5 |
| The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota/Experiment 5/Signature 1 |
| The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota/Experiment 5/Signature 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1/Signature 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2/Signature 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3/Signature 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4/Signature 2 |
| The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial |
| The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial/Experiment 1 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 1 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 1/Signature 1 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 1/Signature 2 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 2 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 2/Signature 1 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 2/Signature 2 |
| The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls/Experiment 2/Signature 1 |
| The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 1/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 2 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 2/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 3 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 4 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 5 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 5/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 5/Signature 2 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 6 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 6/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 6/Signature 3 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 7 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 7/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 8 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 8/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 8/Signature 2 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 9 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 9/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 9/Signature 2 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 10 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 10/Signature 1 |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome/Experiment 1 |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome/Experiment 1/Signature 1 |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome/Experiment 1/Signature 2 |
| The gut microbiota and metabolite profiles are altered in patients with spinal cord injury |
| The gut microbiota and metabolite profiles are altered in patients with spinal cord injury/Experiment 1 |
| The gut microbiota and metabolite profiles are altered in patients with spinal cord injury/Experiment 1/Signature 1 |
| The gut microbiota and metabolite profiles are altered in patients with spinal cord injury/Experiment 1/Signature 2 |
| The gut microbiota and metabolite profiles are altered in patients with spinal cord injury/Experiment 2/Signature 2 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 1 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 1/Signature 1 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 2 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 2/Signature 1 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 3 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 3/Signature 1 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 3/Signature 2 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 4 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 4/Signature 1 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 1 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 1/Signature 1 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 1/Signature 2 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 2 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 2/Signature 1 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 2/Signature 2 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 3 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 3/Signature 1 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 3/Signature 2 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 4 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 4/Signature 1 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 4/Signature 2 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 5 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 5/Signature 1 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 5/Signature 2 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 6 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 6/Signature 1 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 6/Signature 2 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 7 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 7/Signature 1 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 7/Signature 2 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 8 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 8/Signature 1 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 8/Signature 2 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 9 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 10 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 11 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 12 |
| The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels/Experiment 13 |
| The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder/Experiment 4/Signature 2 |
| The nasal microbiome in asthma/Experiment 2 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 1 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 1/Signature 1 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 2 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 2/Signature 1 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 3 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 3/Signature 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 1/Signature 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 2 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 2/Signature 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 3 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 3/Signature 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 4 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 4/Signature 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 1/Signature 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 1/Signature 2 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 2 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 2/Signature 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 2/Signature 2 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 3 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 3/Signature 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 3/Signature 2 |
| Tobacco exposure associated with oral microbiota oxygen utilization in the New York City Health and Nutrition Examination Study/Experiment 3/Signature 1 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 1 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 1/Signature 1 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 1/Signature 2 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 2 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 2/Signature 1 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 2/Signature 2 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 3 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 3/Signature 1 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 3/Signature 2 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 4 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 4/Signature 1 |
| Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome/Experiment 4/Signature 2 |
| Vaginal Microbiome in Pregnant Women with and without Short Cervix |
| Vaginal Microbiome in Pregnant Women with and without Short Cervix/Experiment 1 |
| Vaginal Microbiome in Pregnant Women with and without Short Cervix/Experiment 1/Signature 1 |
| Vaginal microbiomes of breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms |
| Vaginal microbiomes of breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms/Experiment 1 |
| Vaginal microbiomes of breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms/Experiment 1/Signature 1 |
| Vaginal microbiomes of breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms/Experiment 1/Signature 2 |
| White-nose syndrome restructures bat skin microbiomes |
| White-nose syndrome restructures bat skin microbiomes/Experiment 1 |
| White-nose syndrome restructures bat skin microbiomes/Experiment 1/Signature 1 |
| White-nose syndrome restructures bat skin microbiomes/Experiment 1/Signature 2 |
| White-nose syndrome restructures bat skin microbiomes/Experiment 2 |
| White-nose syndrome restructures bat skin microbiomes/Experiment 3 |
| White-nose syndrome restructures bat skin microbiomes/Experiment 3/Signature 1 |
| White-nose syndrome restructures bat skin microbiomes/Experiment 3/Signature 2 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 1/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 1/Signature 2 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 2 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 3 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 4 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 5 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 6 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 6/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 6/Signature 2 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 7 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 7/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 8 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 8/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 9 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 9/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 10 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 10/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 11 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 11/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 12 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 12/Signature 1 |
